Wockhardt Limited (WOCKPHARMA) stock breaks out, gaining 5% intraday to ₹2018.0, clearing its 6M resistance trendline.
Wockhardt Limited (WOCKPHARMA) showcases innovation, performance, and growth at its June 2026 investor conference.
Wockhardt Limited (WOCKPHARMA) receives U.S. FDA approval for ZAYNICH™, a novel antibiotic for treating complicated urinary tract infections.
Wockhardt Limited (WOCKPHARMA) receives CDSCO approval for Zaynich® antibiotic for treating complicated urinary tract infections.